Enhanced Accessibility Announced
A significant shift in access to advanced medical treatments for chronic conditions like type 2 diabetes and obesity is now underway in India. Pharmaceutical
giant Novo Nordisk India has revealed substantial price reductions for its renowned semaglutide injections, Ozempic and Wegovy. This strategic move comes shortly after the emergence of generic alternatives in the Indian market, signaling a new era of affordability. As of April 1, 2026, patients can anticipate a notable decrease in costs. Specifically, the starting dose of Ozempic will see a price reduction of 36 percent, while the starting dose of Wegovy will be reduced by an impressive 48 percent. This initiative aims to make these scientifically validated and clinically proven therapies available to a much wider demographic across the nation, addressing the significant health burdens associated with these conditions.
New Pricing Structure
The revised pricing structure for the starting doses of Ozempic (0.25 mg) and Wegovy (0.25 mg) in India has been detailed. These treatments will now be available at a more accessible effective daily cost of Rs 202, or a weekly cost of Rs 1,415, inclusive of all applicable taxes. This adjustment makes these innovative medications substantially more affordable compared to their initial launch prices. The company's decision to implement these price cuts is a direct response to the ongoing efforts to ensure that highly effective treatments, backed by rigorous scientific research and clinical evidence, reach a greater number of individuals managing diabetes and obesity. The objective is to alleviate the immense pressure these conditions place on the Indian healthcare system and individual well-being.
Commitment to Health Equity
Novo Nordisk India's Managing Director, Vikrant Shrotriya, articulated the company's clear vision behind this pricing revision. The core aim is to democratize access to best-in-class cardiometabolic care. By making these treatments more affordable, the company is striving to reach as many people in India as possible who are dealing with type 2 diabetes, being overweight, or facing obesity. Shrotriya emphasized the substantial health and economic burden that these conditions, along with their related complications, impose on India. He expressed a strong commitment to mitigating this challenge by providing effective, safe, and well-established solutions. This proactive pricing strategy is a testament to the company's dedication to improving public health outcomes and fostering a healthier future for the nation.
